PATENT CLAIM ANALYSIS

Application Number: 16041167
Application Type: Utility
Filing Date: 2018-07
Publication Date: 2019-01
Patent Classification: ["424", "208100"]

Abstract:
Methods for inducing safe and effective immune response against multiple clades of Human Immunodeficiency Virus (HIV) infection in human subjects are described. The methods involve heterologous vaccine combinations of adenovirus serotype 26 expression vectors expressing at least three mosaic HIV antigens with at least one isolated HIV gp140 protein.

Claim (Index 12):
The method of  claim 11 , comprising:\n (1) administering to the subject a priming composition comprising at least three Ad26 vectors together encoding at least three HIV antigenic polypeptides having the amino acid sequences of SEQ ID NO: 1, SEQ ID: NO 3, and SEQ ID NO: 4, respectively, and a pharmaceutically acceptable carrier, in a total dose of about 5\u00d710 10  viral particles (vp) of the Ad26 vectors; (2) administering to the subject, about 12 weeks after (1), the priming composition at a total dose of about 5\u00d710 10  vp of the Ad26 vectors; (3) administering to the subject, about 24 weeks after (1), a first boosting composition comprising at least one isolated HIV envelope glycoprotein having the amino acid sequence of SEQ ID NO: 5, an aluminum phosphate adjuvant and a pharmaceutically acceptable carrier, at a total dose of about 250 \u03bcg of the at least one isolated HIV envelope glycoprotein; (4) administering to the subject, together with (3), a second boosting composition comprising the at least three Ad26 vectors and a pharmaceutically acceptable carrier, at a total dose of about 5\u00d710 10  vp of the Ad26 vectors; (5) administering to the subject, about 48 weeks after (1), the first boosting composition at a total dose of about 250 \u03bcg of the at least one isolated HIV envelope glycoprotein; and (6) administering to the subject, together with (5), the second boosting composition at a total dose of about 5\u00d710 10  vp of the Ad26 vectors; wherein the safe and effective immune response comprises a humoral immune response against HIV clades A, B and C at a median response rate of at least 90%, as measured by IgG bindings to HIV envelope glycoproteins from clades A, B and C in enzyme-linked immunosorbent assays (ELISAs).

Metadata:
- Claim Count in Document: 50.0
- Percentile: 95.0
- Lexical Diversity: 1.12766
- Patent Class: 424.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['15968834', '14863808', '15693650', '15380123', '13130018']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.718702881456068
- 35 USC 102 Novelty (BERT): 0.5973547111951976
- Combined Prediction Score: 0.7065680644299809
- Mean Citation Score: 472.678518
- Max Citation Score: 600.1256
- Similarity Product: 411.9035670249939

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 0
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test